TA-MUC1-H + EGFR positive
|
CRC
|
TA-MUC1-H + EGFR positive
|
CRC
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
TA-MUC1-H + EGFR positive
|
Breast Cancer
|
TA-MUC1-H + EGFR positive
|
Breast Cancer
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
TA-MUC1-H + EGFR positive
|
Head and Neck Cancer
|
TA-MUC1-H + EGFR positive
|
Head and Neck Cancer
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
TA-MUC1-H + EGFR positive
|
NSCLC
|
TA-MUC1-H + EGFR positive
|
NSCLC
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|
gatipotuzumab + tomuzotuximab Sensitive: C3 – Early Trials
|